Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by the public in African Union Member States.
Currently..., there is:
1. No scientific evidence from pre-clinical studies on the therapeutic effect of ivermectin for the management of COVID-19;
2. No evidence of its clinical efficacy for the management of patients with asymptomatic, mild, moderate or severe COVID-19; and
3. No safety data regarding the use of ivermectin for COVID-19 in the majority of the published studies.
more
“Guide to facilitate the implementation of the WHO/UNICEF “Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines” for Africa
The official death toll had risen to 493 people as of 29 March, according to the Government.
A new cholera outbreak was reported in Nhamatande; nine Cholera Treatment Centres have been established in Beira and other locations.
More than 140,000 people were displaced in 161 sites across Sofala (116... sites), Manica (27 sites), Zambezia (13 sites) Tete (5 sites); of whom more than 7,400 were identified as vulnerable, according to the Government.
more
Since there is no single objective diagnostic test for asthma this study suggests an approach of collecting and assembling pieces of clinical information to create a diagnostic picture, like making a jigsaw puzzle. These pieces should include demonstration of symptom and airway variability and/or br...onchodilator responsiveness over time, to support a clinical diagnosis.
more
Presentation on chikungunya a and chikungunya vaccines
Prepared by the Independent Panel for Pandemic Preparedness and Response for the WHO Executive Board, January 2021
“The world was not as prepared as it should have been, and it must do better,” concludes a WHO panel reviewing the pandemic response "
Trop. Med. Infect. Dis. 2022, 7, 152. https://doi.org/10.3390/tropicalmed7080152
(For enhanced adherence counseling [EAC] and second-line ART consideration)